NHI.no
Annonse
Informasjon

Systemisk sklerose (sklerodermi)

Systemisk sklerose er en bindevevssykdom som angriper mange organer og gir uttalt bindevevsdannelse, såkalt sklerose. Huden angripes nesten alltid. Prognosen avhenger av hvilken type systemisk sklerose det er.

Systemisk sklerose kan gi mange ulike symptomer, blant annet hudforandring, svelgvansker, kortpustet, leddsmerter og svakhet.

Sist oppdatert:

13. juli 2020

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Systemisk sklerose . Referanselisten for dette dokumentet vises nedenfor

  1. Kowal-Bielecka O, Fransen J, Avouac J EUSTAR Coauthors, et alUpdate of EULAR recommendations for the treatment of systemic sclerosisAnnals of the Rheumatic Diseases 2017;76:1327-1339. ard.bmj.com
  2. Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Seminar. Lancet 2022. pmid:36442487 PubMed
  3. Schwartz RA. Systemic sclerosis. Medscape, last updated Mar 13, 2018. emedicine.medscape.com
  4. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37: 223-35. pmid:17692364 PubMed
  5. Gran JT, Molberg Ø, Midtvedt Ø. Patofysiologiske aspekter ved systemisk sklerose. Tidsskr Nor Lægeforen 2005; 125: 2622-3. PubMed
  6. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603-10. PubMed
  7. Varga J. Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Jan 06, 2017. UpToDate
  8. Varga J. Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Jan 05, 2017. UpToDate
  9. Gran JT, Midtvedt Ø. Iskemiske sår ved systemisk bindevevssykdom. Tidsskr Nor Lægeforen 2006; 126: 3089-92. PubMed
  10. Kuwana M. Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting. J Nippon Med Sch 2017; 84(2): 56-63. pmid:28502960 PubMed
  11. Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. C - reactive protein (CRP) is associated with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG). Arthritis Care Res (Hoboken). 2012; 64(9):1405-14. PubMed
  12. Derrett-Smith EC, Nihtyanova SI, Harvey J, et al. Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (Oxford) 2013; 52:1824. PubMed
  13. Denton CP. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. UpToDate, last updated Oct 10, 2014. UpToDate
  14. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015 Jun; 74:1188. Doi: 10.1136/annrheumdis-2013-204522 DOI
  15. Kuzumi A, Ebata S, Fukasawa T, et al. Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels. JAMA Dermatol 2023; 159: 374-383. pmid:36790794 PubMed
  16. Tashkin DP, Roth MD, Clements PJ et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet respir Med 2016; 4: 708. doi:27469583
  17. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 PMID: 31112379 PubMed
  18. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014 Jun 25;311(24):2490-8. PubMed
  19. Sullivan KM., Goldmuntz EA., Keyes-Elstein L. et al.. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378: 35-47. pmid:29298160 PubMed
  20. Onishi A, Sugiyama D, Kumagai S, et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013 Jul;65(7):1913-21. doi: 10.1002/art.37969. DOI
  21. Tennøe AH, Murbræch K, Andreassen JC, et al. Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis. Journal of the American College of Cardiology, volume 72, issue 15, October 2018.
  22. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809. PubMed
Annonse
Annonse